SecBot SecBot
8-K ·Filed Aug 10, 2026

HROW

HARROW, INC.
MIXED
Impact 6/10
Horizonweeks Processed2mo ago SEC0001493152-26-036865
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The massive H2 ramp implied by guidance (H1 revenue $114.9M vs. full-year $350M-$365M) is the key swing factor. Monitor weekly prescription data for VEVYE and IHEEZO unit demand to validate the inflection. The GAAP loss and negative operating cash flow mean the company is burning cash to invest — watch for any guidance revision or capital raise if H2 execution falters.

DirectionMixed
Confidencehigh
Horizonweeks
Latest settled — T+20d ⚠ clustered
HROW ▼ -4.74% at T+20d
NEUTRAL call -4.74% · α vs SPY -3.68% · entry $39.42 → $37.55
Next anchor: T+60d in 6d
Latest observation: T+52 -38.19% FF3 residual α
Entry = T+0 close
Aug 10, 2026
via day close
T+1d
-0.15%
call -0.15% · α -0.40%
$39.36
settled 3mo ago
T+5d
+0.25%
call +0.25% · α +0.66%
$39.52
settled 2mo ago
T+20d
-4.74%
call -4.74% · α -3.68%
$37.55
settled 7w ago
T+60d
Pending
in 6d

Price Chart

Loading chart...

Executive Summary

Harrow reported Q2 2026 revenue of $70.7M, an 11% YoY increase and a 60% sequential jump, driven by strong branded product growth (VEVYE +58% YoY, IHEEZO record unit demand). However, GAAP net loss was -$17.3M vs. +$5.0M a year ago, and Adjusted EBITDA swung to -$1.2M from +$17.0M, reflecting heavy investment in sales force expansion and R&D. The company reiterated full-year 2026 guidance of $350M-$365M revenue and $80M-$100M Adjusted EBITDA, implying a massive H2 ramp. The TYRVAYA acquisition and BYOOVIZ launch add pipeline catalysts, but the GAAP loss and negative cash flow from operations (-$18.7M YTD) raise execution risk on the back-half guidance.

Key Financial Metrics

EPS
−$0.34
est $0.38 · -189.5%
Revenue
$70.7M
est $101.7M · -30.5% · +11.0% YoY
Rating
miss
Guidance
$350M-$365M
maintained
Gross Margin
71%

Key Facts

  • Q2 2026 revenue $70.7M, +11% YoY, +60% sequential
  • GAAP net loss -$17.3M vs. +$5.0M YoY; Adjusted EBITDA -$1.2M vs. +$17.0M YoY
  • VEVYE revenue $29.4M, +58% YoY; IHEEZO unit demand +44% sequential, +34% YoY
  • Full-year 2026 guidance reiterated: revenue $350M-$365M, Adj. EBITDA $80M-$100M
  • TYRVAYA acquisition announced, expected to close H2 2026; BYOOVIZ launched July 2026
  • Cash and equivalents $83.9M; operating cash flow -$18.7M YTD
  • SG&A surged to $53.3M from $33.2M YoY; R&D $8.1M from $2.9M YoY

Financial Impact

Revenue $70.7M (+11% YoY), GAAP net loss -$17.3M, Adj. EBITDA -$1.2M; full-year guidance implies H2 revenue ~$235M-$250M

revenuenet incomeadjusted EBITDAoperating cash flowSG&AR&D

Risk Factors

  • Guidance implies H2 revenue more than double H1 — execution risk on sales force ramp and VEVYE/IHEEZO conversion
  • GAAP net loss and negative operating cash flow (-$18.7M YTD) could pressure liquidity if H2 ramp disappoints
  • ImprimisRx revenue declined 32% YoY to $14.6M; recovery dependent on inventory rebuild and market exit stabilization
  • TYRVAYA acquisition integration and BYOOVIZ launch add near-term complexity and cost
  • Debt of $292.4M vs. equity of $14.8M — high leverage amplifies downside risk

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-036865
Exhibit: ex99-1.htm0001493152-26-036865
Document: form8-k.htm0001493152-26-036865
Document: 0001493152-26-036865-index-headers.html0001493152-26-036865
Document: 0001493152-26-036865-index.html0001493152-26-036865
Document: 0001493152-26-036865.txt0001493152-26-036865
8-K Data (Synthetic)0001493152-26-036865
17 reports for HROW
Performance horizon
67% Hit rate @ T+1 4 of 6 directional calls Went positive at some point 4 of 6 best @ T+20▲ +36.70%May 19, 2026
Filters
Rows
Reports for HROW — sortable, filterable
TypeNow
Oct 27, 2026
today
SC 13G/A
NEUTRAL ★ 2/10
$29.10awaiting T+1—$29.07 (−0.10%)
Oct 5, 2026
22d ago
8-K
BULLISH ★ 7/10
$30.58 $30.35▼ −0.75%▼ −1.30%$29.07 (−4.94%)
Oct 5, 2026
22d ago
Press Release
BULLISH ★ 6/10
$30.58 $30.35▼ −0.75%▼ −1.30%$29.07 (−4.94%)
Aug 10, 2026
11w ago
8-K
MIXED ★ 6/10
$39.42 $39.36▼ −0.15%▼ −0.40%$29.07 (−26.26%)
Aug 10, 2026
11w ago
Press Release
BEARISH ★ 8/10
$39.42 $39.36▲ +0.15%▲ +0.40%$29.07 (+26.26%)
Aug 6, 2026
11w ago
8-K
BULLISH ★ 7/10
$39.92 $40.44▲ +1.30%▲ +0.69%$29.07 (−27.18%)
Jul 27, 2026
13w ago
Press Release
NEUTRAL ★ 1/10
$37.46awaiting T+1—$29.07 (−22.40%)
Jul 20, 2026
14w ago
Press Release
NEUTRAL ★ 5/10
$44.45 $43.71▼ −1.66%▼ −2.50%$29.07 (−34.60%)
Jun 11, 2026
19w ago
Institutional Cluster
MIXED ★ 5/10
$37.64 $38.93▲ +3.43%▲ +1.66%$29.07 (−22.77%)
Jun 11, 2026
19w ago
Institutional Cluster
MIXED ★ 4/10
$37.65 $37.64▼ −0.03%▼ −0.57%$29.07 (−22.79%)
Showing 10 of 17

US Market Status

Market Closed — Opens Thu (11h 34m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 10, 2026